KR880013575A - 안정한 동결건조된 생체 헤르페스 바이러스 백신 - Google Patents

안정한 동결건조된 생체 헤르페스 바이러스 백신 Download PDF

Info

Publication number
KR880013575A
KR880013575A KR1019880005135A KR880005135A KR880013575A KR 880013575 A KR880013575 A KR 880013575A KR 1019880005135 A KR1019880005135 A KR 1019880005135A KR 880005135 A KR880005135 A KR 880005135A KR 880013575 A KR880013575 A KR 880013575A
Authority
KR
South Korea
Prior art keywords
vaccine
lyophilized
herpes virus
virus vaccine
water content
Prior art date
Application number
KR1019880005135A
Other languages
English (en)
Other versions
KR960016581B1 (ko
Inventor
제이.멕알리어 윌리암
제트.마커스 헨리
제트.메이게터 로버트
Original Assignee
제임스 에프.너튼
머크 앤드 컴퍼니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프.너튼, 머크 앤드 컴퍼니 인코포레이티드 filed Critical 제임스 에프.너튼
Publication of KR880013575A publication Critical patent/KR880013575A/ko
Application granted granted Critical
Publication of KR960016581B1 publication Critical patent/KR960016581B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

안정한 동결건조된 생체 헤르페스 바이러스 백신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 수분함량이 약0.5내지 약8%임을 특징으로 하는 가스주입식 동결건조된 생체 헤르페스 바이러스 백신.
  2. 제1항에 있어서, 수분함량이 약0.5내지 약2%인 동결건조된 생체 헤르페프 바이러스 백신.
  3. 제1항에 있어서, 수분함량이 약2내지 약5%인 동결건조된 생체 헤르페프 바이러스 백신.
  4. 제1항에 있어서, 수분함량이 약5내지 약8%인 동결건조된 생체 헤르페프 바이러스 백신.
  5. 제1항에 있어서, 헤르페스 바이러스가 수두인 동결건조된 생체 헤르페프 바이러스 백신.
  6. 홍역 백신, 유행성 이하선염 백신 및 풍진 백신(여기에서 각각의 백신은 각각의 바이러스에 대해 수용체를 면역시키기에 유효한 양으로 존재한다)과 혼합되어 수분함량이 약0.5내지 약8%인 4가의 동결건조된 백신을 형성하는 동결건조된 생체 헤르페스 바이러스 백신
  7. 제6항에 있어서, 동결건조된 백신의 수분함량이 약0.5내지 약2%인 백신.
  8. 제6항에 있어서, 동결건조된 생체 백신의 수분함량이 약2내지 약5%인 백신.
  9. 제6항에 있어서, 동결건조된 생체 백신의 수분 약5내지 약8%인 백신.
  10. 일차 주기와 이차 주기의 총 시간이 약 7내지 약 11시간인, 가스주입을 통한 일차 주기 및 이차 주기를 포함하는, 제6항의 생체 헤르페스 바이러스 백신의 동결건조 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880005135A 1987-05-04 1988-05-03 가스주입식으로 동결건조시킨 약독화된 수두 바이러스 생균 백신 KR960016581B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4594087A 1987-05-04 1987-05-04
US045,940 1987-05-04

Publications (2)

Publication Number Publication Date
KR880013575A true KR880013575A (ko) 1988-12-21
KR960016581B1 KR960016581B1 (ko) 1996-12-16

Family

ID=21940663

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880005135A KR960016581B1 (ko) 1987-05-04 1988-05-03 가스주입식으로 동결건조시킨 약독화된 수두 바이러스 생균 백신

Country Status (16)

Country Link
EP (1) EP0290197B1 (ko)
JP (1) JP2643982B2 (ko)
KR (1) KR960016581B1 (ko)
AT (1) ATE95427T1 (ko)
AU (1) AU622110B2 (ko)
CA (1) CA1324956C (ko)
DE (1) DE3884663T2 (ko)
DK (1) DK238688A (ko)
FI (1) FI94093C (ko)
HK (1) HK5997A (ko)
IE (1) IE61575B1 (ko)
IL (1) IL86180A (ko)
NO (1) NO176163C (ko)
NZ (1) NZ224419A (ko)
PT (1) PT87388B (ko)
ZA (1) ZA883133B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2000034A6 (es) * 1985-11-26 1987-10-01 Schweiz Serum & Impfinst Procedimiento para la preparacion de una vacuna viva contra paperas
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
IL148247A0 (en) 1999-08-24 2002-09-12 Teva Pharma A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
WO2008057550A2 (en) 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
AU2012245198B2 (en) * 2011-04-21 2017-07-13 Trustees Of Tufts College Compositions and methods for stabilization of active agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (ko) * 1974-03-12 1978-11-01
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
DK331087A (da) * 1986-06-30 1987-12-31 Smith Kline Rit Stabilisator for levende vaccine

Also Published As

Publication number Publication date
NO176163C (no) 1995-02-15
PT87388A (pt) 1989-05-31
DK238688A (da) 1988-11-05
DE3884663T2 (de) 1994-04-07
PT87388B (pt) 1992-08-31
FI94093C (fi) 1995-07-25
DE3884663D1 (de) 1993-11-11
AU1552788A (en) 1988-11-10
HK5997A (en) 1997-01-17
JP2643982B2 (ja) 1997-08-25
ZA883133B (en) 1988-11-08
FI882041A0 (fi) 1988-05-02
NO881931L (no) 1988-11-07
DK238688D0 (da) 1988-05-03
EP0290197B1 (en) 1993-10-06
JPS646220A (en) 1989-01-10
IL86180A (en) 1992-08-18
NO881931D0 (no) 1988-05-03
ATE95427T1 (de) 1993-10-15
AU622110B2 (en) 1992-04-02
IE61575B1 (en) 1994-11-16
FI94093B (fi) 1995-04-13
NO176163B (no) 1994-11-07
IE881248L (en) 1988-11-04
KR960016581B1 (ko) 1996-12-16
EP0290197A2 (en) 1988-11-09
CA1324956C (en) 1993-12-07
EP0290197A3 (en) 1989-10-18
NZ224419A (en) 1991-03-26
FI882041A (fi) 1988-11-05
IL86180A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
DE3679708D1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DK122184A (da) Indretning til mikrobiologisk afproevning
NO913558D0 (no) Fremgangsmaate ved fremstilling av xenogene antistoffer.
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
SE8403010D0 (sv) A device for combustion of a fuel and oxygen mixed with a part of the combustion gases formed during the combustion
BR8905851A (pt) Processo para a deteccao de uma infeccao por aids em seres humanos;composicao de proteina de involucro do virus de aids;e kit de teste utilizavel na administracao intradermica para deteccao de uma infeccao por aids
ATE247708T1 (de) Verfahren zur regulierung der metabolischen stabilität von proteinen
DK325486A (da) Fremgangsmaade til fremme af bakteriers vedhaeftning til mave-tarmkanali dyr og mennesker samt praeparat til anvendelse ved fremgangsmaaden
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
KR890000107A (ko) 안정화된 생 비루스 백신 및 그의 제조법
KR880013575A (ko) 안정한 동결건조된 생체 헤르페스 바이러스 백신
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
ES548397A0 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
DE69101634T2 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
ATE202925T1 (de) Impfpackung enthaltend ein behälter mit gefriertrockenen impfkomponenten
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
ATE179457T1 (de) Zuwachsfaktorrezeptorgen deriviert von platten des typs oc
DE69801036D1 (de) Verfahren zur Wärmebehandlung von Holz
DK87190A (da) Fremgangsmaade til at regulere plantevaekst under anvendelse af svovlholdige organiske syrer
DE69018755T2 (de) Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten.
DK76687A (da) Fremgangsmaade til fremstilling af indol-alfa-ketosyrer ud fra den tilsvarende alfa-aminosyre, navnlig til fremstilling af indolpyrodruesyre
PT86552A (de) Gama-glutamyl-transpeptidase deren herstellung und deren verwendung
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
KR890006254A (ko) 비-특이적 면역성 인듀서의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021031

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee